AnaptysBio (NASDAQ:ANAB) Posts Quarterly Earnings Results, Misses Estimates By $0.06 EPS

AnaptysBio (NASDAQ:ANAB) issued its quarterly earnings data on Friday. The biotechnology company reported ($1.15) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($1.09) by ($0.06), reports. During the same period last year, the business posted ($0.66) earnings per share.

ANAB traded down $25.98 during trading on Friday, reaching $10.18. The stock had a trading volume of 17,702,700 shares, compared to its average volume of 366,688. AnaptysBio has a 1-year low of $10.00 and a 1-year high of $83.10. The firm has a market capitalization of $1.05 billion, a price-to-earnings ratio of -4.07 and a beta of 1.50. The stock has a 50 day moving average of $36.21 and a two-hundred day moving average of $53.30.

Several equities analysts have recently issued reports on the company. Guggenheim downgraded AnaptysBio from a “buy” rating to a “neutral” rating in a research report on Friday. BidaskClub upgraded AnaptysBio from a “strong sell” rating to a “sell” rating in a research report on Friday, October 18th. Wedbush downgraded AnaptysBio from an “outperform” rating to a “neutral” rating in a research report on Friday. SunTrust Banks downgraded AnaptysBio from a “buy” rating to a “hold” rating in a research report on Friday. Finally, Cantor Fitzgerald set a $140.00 target price on AnaptysBio and gave the stock a “buy” rating in a research report on Tuesday, August 20th. Two investment analysts have rated the stock with a sell rating, six have assigned a hold rating and four have assigned a buy rating to the company’s stock. The stock currently has an average rating of “Hold” and an average price target of $75.11.

AnaptysBio Company Profile

AnaptysBio, Inc, a clinical stage biotechnology company, engages in developing antibody product candidates focused on unmet medical needs in inflammation. The company's products include Etokimab, an anti-interleukin (IL)-33 program for the treatment of atopic dermatitis, eosinophilic asthma, and chronic rhinosinusitis with nasal polyps; ANB019, an anti-IL-36 receptor program for generalized pustular psoriasis and palmo-plantar pustular psoriasis; and anti-inflammatory checkpoint modulators for inflammatory diseases.

Featured Story: What is a management fee?

Earnings History for AnaptysBio (NASDAQ:ANAB)

Receive News & Ratings for AnaptysBio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AnaptysBio and related companies with's FREE daily email newsletter.